Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trialElizabeth A. Mittendorf, Nadia Harbeck, Hiroji Iwata et al.|The Lancet|2020Cited by 1.1k
Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trialThomas Powles, Felipe Reyes, Tibor Csőszi et al.|The Lancet Oncology|2021Cited by 645
Identification of Hypermutation and Defective Mismatch Repair in ctDNA from Metastatic Prostate CancerElie Ritch, Alexander W. Wyatt, Simon Fu et al.|Clinical Cancer Research|2019Cited by 77
Figure S7 from Identification of Hypermutation and Defective Mismatch Repair in ctDNA from Metastatic Prostate CancerElie Ritch, Alexander W. Wyatt, Simon Fu et al.|Unknown|2023Cited by 0